20 Nov 2012, BioSpectrum Bureau , BioSpectrum
Hyderabad: GVK Biosciences, Asia's leading drug discovery R&D organization, has received approvals from the Atomic Energy Regulatory Board (AERB), Government of India, to carry out 3H and 14C isotope synthesis activities.
GVK's facility is GLP compliant and has state-of-the-art equipment to cater to the requirements of companies engaged in the fields of drug discovery and development, agro and veterinary chemicals, cosmetics, perfumery and specialty studies.
Speaking of this development, Mr Manni Kantipudi, CEO, GVK BIO, said, "Several of our customers requested us to extend our chemistry services to include isotope labeling services. We listened to our customers and setup this state-of-the art facility which is the largest such facility in India. The facility has received all statutory approvals from the Atomic Energy Review Board of India."